Spesific Antibody Deficiency

immunoloji-17-1-2024

Ümmügülsüm YILMAZa , Eray YILDIZb
aNecmettin Erbakan University Faculty of Medicine, Department of Internal Medicine, Division of Clinical Immunology and Allergy Diseases, Konya, Türkiye
bKahramanmaraş Necip Fazıl City Hospital, Clinic of Immunology and Allergy Diseases, Kahramanmaraş, Türkiye

Yılmaz Ü, Yıldız E. Spesific antibody deficiency. Çölkesen F, ed. Primary Immunodeficiency Diseases in Adults. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.38-44.

ABSTRACT
Specific antibody deficiency (SAD) is characterized by a defective antibody response to polysaccharide antigens, while the immune reaction against protein antigens is preserved. Patients have normal levels of serum immunoglobulins; IgG, M, A, E and IgG subgroups. Diagnosis, treatment, and follow-up are important. Because there have been reports of SAD evolving into CVID. In this review, the clinical presentation, diagnosis, treatment and follow-up of SAD would be discussed. In addition, pneumococcal vaccines and vaccine responses would be mentioned.

Keywords: Primary immunodeficiency diseases; spesific antibody deficiency; pneumococcal vaccines

Referanslar

  1. Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96-128. [Crossref]  [PubMed]  [PMC]
  2. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 2009;22(3):396-414. [Crossref]  [PubMed]  [PMC]
  3. Alachkar H, Taubenheim N, Haeney MR, Durandy A, Arkwright PD. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol. 2006;120(3):310-8. [Crossref]  [PubMed]
  4. Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473-507. [Crossref]  [PubMed]  [PMC]
  5. Carr TF, Koterba AP, Chandra R, Grammer LC, Conley DB, Harris KE, et al. Characterization of specific antibody deficiency in adults with medically refractory chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25(4):241-4. [Crossref]
  6. Ocampo CJ, Peters AT. Antibody deficiency in chronic rhinosinusitis: epidemiology and burden of illness. Am J Rhinol Allergy. 2013;27(1):34-8. [Crossref]  [PubMed]  [PMC]
  7. Epstein MM, Gruskay F. Selective deficiency in pneumococcal antibody response in children with recurrent infections. Ann Allergy Asthma Immunol. 1995;75(2):125-31.
  8. Hidalgo H, Moore C, Leiva LE, Sorensen RU. Preimmunization and postimmunization pneumococcal antibody titers in children with recurrent infections. Ann Allergy Asthma Immunol. 1996;76(4):341-6. [Crossref]  [PubMed]
  9. Ekdahl K, Braconier JH, Svanborg C. Immunoglobulin deficiencies and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia. Scand J Infect Dis. 1997;29(4):401-7. [Crossref]  [PubMed]
  10. Lawrence MG, Borish L. Specific antibody deficiency: pearls and pitfalls for diagnosis. Ann Allergy Asthma Immunol. 2022;129(5):572-8. [Crossref]  [PubMed]
  11. van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J. 2005;25(3):482-9. [Crossref]  [PubMed]
  12. Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: A multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344-53. [Crossref]  [PubMed]
  13. Shin JJ, Liauw D, Siddiqui S, Lee J, Chung EJ, Steele R, et al. Immunological and Clinical Phenotyping in Primary Antibody Deficiencies: a Growing Disease Spectrum. J Clin Immunol. 2020;40(4):592-601. [Crossref]  [PubMed]  [PMC]
  14. Paris K, Orange JS, Feldweg A W, Spesific Antibody Deficiency, Wolters Kluwers Health, 2022, [Link]
  15. Sorensen RU, Moore C. Antibody deficiency syndromes. Pediatr Clin North Am. 2000;47(6):1225-52. [Crossref]  [PubMed]
  16. Sorensen RU, Hidalgo H, Moore C, Leiva LE. Post-immunization pneumococcal antibody titers and IgG subclasses. Pediatr Pulmonol. 1996;22(3):167-73. [Crossref]
  17. Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T. Pneumococcal vaccination: what have we learnt so far and what can we expect in the future? Eur J Clin Microbiol Infect Dis. 2015;34(1):19-31. Erratum in: Eur J Clin Microbiol Infect Dis. 2015;34(2):415-6. [Crossref]  [PubMed]  [PMC]
  18. Şenol E, Azap A, Erbay A, Alp-Çavuş S, Karakuş R, Acar A. Erişkin bağışıklamasının hedefindeki aşılardan biri olarak pnömokok aşısı: Türk klinik mikrobiyoloji ve infeksiyon hastalıkları derneği erişkin bağışıklaması çalışma grubu uzlaşı raporu. Klimik Dergisi. 2018;31(1):2-18. [Crossref]
  19. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2012;130(3 Suppl):S1-24. [Crossref]  [PubMed]
  20. Perez E, Bonilla FA, Orange JS, Ballow M. Specific Antibody Deficiency: Controversies in Diagnosis and Management. Front Immunol. 2017;8:586. Erratum in: Front Immunol. 2018;9:450. [Crossref]  [PubMed]  [PMC]
  21. Bausch-Jurken MT, Verbsky JW, Gonzaga KA, Elms NP, Hintermeyer MK, Gauld SB, et al. The Use of Salmonella Typhim Vaccine to Diagnose Antibody Deficiency. J Clin Immunol. 2017;37(5):427-33. [Crossref]  [PubMed]
  22. Sorensen RU, Leiva LE, Giangrosso PA, Butler B, Javier FC 3rd, Sacerdote DM, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis J. 1998;17(8):685-91. [Crossref]  [PubMed]
  23. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-9. [Crossref]
  24. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al.; Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the Joint Council of Allergy, Asthma & Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186-205.e1-78.
  25. Cohn JA, Skorpinski E, Cohn JR. Prevention of pneumococcal infection in a patient with normal immunoglobulin levels but impaired polysaccharide antibody production. Ann Allergy Asthma Immunol. 2006;97(5):603-5. [Crossref]  [PubMed]
  26. Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol. 2007;99(5):462-4. [Crossref]  [PubMed]